The estimated Net Worth of Patricia L Allen is at least $2.23 Milión dollars as of 3 June 2020. Ms. Allen owns over 12,000 units of Deciphera Pharmaceuticals Inc stock worth over $144,200 and over the last 18 years she sold DCPH stock worth over $1,852,382. In addition, she makes $229,964 as Independent Director at Deciphera Pharmaceuticals Inc.
Patricia has made over 6 trades of the Deciphera Pharmaceuticals Inc stock since 2007, according to the Form 4 filled with the SEC. Most recently she exercised 12,000 units of DCPH stock worth $308,760 on 3 June 2020.
The largest trade she's ever made was selling 25,000 units of Deciphera Pharmaceuticals Inc stock on 24 January 2020 worth over $1,653,250. On average, Patricia trades about 4,007 units every 177 days since 2006. As of 3 June 2020 she still owns at least 5,635 units of Deciphera Pharmaceuticals Inc stock.
You can see the complete history of Ms. Allen stock trades at the bottom of the page.
Patricia L. Allen CPA serves as Independent Director of the Company. Ms. Allen has served as a member of our Board of Directors and as the Chairperson of the Audit Committee since September 2016. Since 2013, Ms. Allen has served as Chief Financial Officer of Zafgen, Inc. Ms. Allen has over 20 years of financial leadership experience in the biotechnology industry at both publicly traded and private companies. From 2011 to 2012, she provided independent consulting services to biotechnology companies in a variety of areas, including interim chief financial officer services, fundraising, deal structures, financial planning, organizational structure, investor relations and business development. Previously, from 2004 to 2011, Ms. Allen served as the Vice President of Finance, Treasurer and Principal Financial Officer of Alnylam Pharmaceuticals, Inc., a publicly traded biotechnology company. Prior to Alnylam, Ms. Allen was at Alkermes, Inc., a publicly traded biotechnology company, most recently as the Director of Finance. Ms. Allen began her career as an auditor at Deloitte & Touche, LLP. Ms. Allen graduated summa cum laude from Bryant College with a B.S. in business administration.
As the Independent Director of Deciphera Pharmaceuticals Inc, the total compensation of Patricia Allen at Deciphera Pharmaceuticals Inc is $229,964. There are 17 executives at Deciphera Pharmaceuticals Inc getting paid more, with Steven Hoerter having the highest compensation of $9,025,190.
Patricia Allen is 58, she's been the Independent Director of Deciphera Pharmaceuticals Inc since 2016. There are 11 older and 9 younger executives at Deciphera Pharmaceuticals Inc. The oldest executive at Deciphera Pharmaceuticals Inc is Edward Benz, 73, who is the Independent Director.
Patricia's mailing address filed with the SEC is C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET, WALTHAM, MA, 02451.
Over the last 7 years, insiders at Deciphera Pharmaceuticals Inc have traded over $25,274,872 worth of Deciphera Pharmaceuticals Inc stock and bought 3,916,644 units worth $57,831,028 . The most active insiders traders include Liam Ratcliffe, Associates Llc Brightstar a Ron Squarer. On average, Deciphera Pharmaceuticals Inc executives and independent directors trade stock every 17 days with the average trade being worth of $1,218,775. The most recent stock trade was executed by Thomas Patrick Kelly on 15 February 2024, trading 3,010 units of DCPH stock currently worth $47,016.
deciphera was established in 2003 based on a deep scientific understanding of kinase inhibitors and a team dedicated to developing sophisticated approaches to therapeutic targeting of kinases. with business and development operations based in boston, and dedicated research capabilities in close proximity to the university of kansas, deciphera has identified small molecule leads for over 50 kinase targets, and has developed a pipeline of small molecule drug candidates for a range of cancers.
Deciphera Pharmaceuticals Inc executives and other stock owners filed with the SEC include: